HCPLive 5 Stories in Under 5: Week of 02/15
About this episode
A recap of the top 5 healthcare stories from the past week in under 5 minutes.
Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you! Interested in a more traditional, text rundown? Check out the HCPFive ! MAJESTY: Obinutuzumab Achieves 2 Year Complete Remission in Primary Membranous Nephropathy Obinutuzumab demonstrated superior complete remission rates at 2 years compared with tacrolimus in primary membranous nephropathy in the phase 3 MAJESTY trial, supporting a potential new B-cell–targeted standard of care. Ixekizumab, Tirzepatide Effective Together for Psoriasis and Obesity or Overweight In adults with moderate-to-severe plaque psoriasis and obesity or overweight, combination therapy with ixekizumab and tirzepatide achieved superior skin clearance and weight reduction at 36 weeks compared with ixekizumab alone. AREXVY Vaccine Reduces Hospitalization, Major Adverse Cardiovascular Events in RSV Real-world data from over 2.5 million patients showed GSK’s AREXVY vaccine was 75.6% effective against RSV-related hospitalization, with additional…
Keywords
- healthcare stories
- clinical updates
- medical news
More episodes of HCPLive Podcasts
- FSGS Drug Development No Longer a ‘Graveyard’: What Comes After Sparsentan’s Approval
- Liver Lineup: Closing the Gap in Women’s Liver Health
- Liver Lineup: Navigating Genetic Testing in Cholestatic Liver Disease
- HCPLive 5 Stories in Under 5: Week of 03/08
- ICD-10 Adoption and the True Burden of Short Bowel Syndrome With Alan Buchman, MD, MSPH
- When Platelet Increments Matter, With Ruchika Goel, MD
Explore listener stats, chart rankings, contacts and more on the HCPLive Podcasts podcast page.